鄂爾多斯(600295.SH):香港公司累計增持276.93萬股B股
格隆匯 11 月 12日丨鄂爾多斯(600295.SH)公佈,2020年11月12日,公司接到了《鄂爾多斯資產管理(香港)有限公司關於增持內蒙古鄂爾多斯資源股份有限公司股份進展的函》,香港公司已通過上海證券交易所交易系統增持公司B股股份。
截至2020年11月12日,香港公司自此次增持計劃開始至今累計從上海證券交易所交易系統增持公司B股276.9326萬股,增持數量為公司已發行股份的0.1939%,增持總金額為250.28萬美元,已完成公告增持下限500萬美元的一半。
目前集團公司及其一致行動人香港公司合計持有公司股份9.24億股,占上市公司已發行股份的64.7407%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.